Survival and prognostic factors of early ovarian cancer

Villa, Antonella; Parazzini, Fabio; Acerboni, S.; Guarnerio, Paolo; Bolis, Giorgio

doi:10.1038/bjc.1998.19

Cited by 24 publications

(11 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This rate was approximately similar to the survival of patients treated radically reported in the literature. 16,21 However, the survival of patients with Grade 2 early stage diseases was quite different from survival reported in the literature. In the literature, survival of patients with this type of tumor varies from 77% to 94% whereas in our study the DFS in patients with Stage IA Grade 2 tumor was only 68%.…”

Section: Discussioncontrasting

confidence: 45%

“…Patients with clear cell tumors seem to have a worse survival rate than those with serous, mucinous, and endometrioid tumors. 16,19 Therefore, we think that conservative management could be discussed for patients with serous, mucinous, or endometrioid tumors but should not be performed in patients with more aggressive tumors such as clear cell carcinoma.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Results of conservative treatment in epithelial ovarian carcinoma

Morice

Wicart-Poque

Rey

et al. 2001

Cancer

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 45%

Section: Discussionmentioning

confidence: 99%

Results of conservative treatment in epithelial ovarian carcinoma

Morice

Wicart-Poque

Rey

et al. 2001

Cancer

View full text Add to dashboard Cite

“…These findings have also been confirmed by other, smaller studies. 11,14,16,30,[36][37][38][39][40][41][42][43][44] In this current analysis, malignant cytology was an independent prognostic factor for increased risk of recurrence and poorer survival. Early studies have demonstrated that patients with positive washing have a poorer prognosis.…”

Section: Discussionmentioning

confidence: 99%

Prognostic factors for high‐risk early‐stage epithelial ovarian cancer

Chan

Tian

Monk

et al. 2008

Cancer

144

View full text Add to dashboard Cite

BACKGROUND. The purpose was to identify the factors predictive of recurrence and survival in patients with high‐risk (stage I, grade 3; stage IC, stage II, or clear cell) epithelial ovarian cancer after adjuvant therapy. METHODS. Data was extracted from patients who underwent primary surgery followed by adjuvant therapy in 2 randomized trials by the Gynecologic Oncology Group (Protocols 95 and 157). Kaplan‐Meier survival estimates and Cox proportional hazards model adjusted for covariates were used for analyses. RESULTS. Of 506 patients (median age = 56.2 years), 347 (68.6%) had stage I and 159 (31.4%) had stage II cancers. The 5‐year recurrence‐free (RFS) and overall survivals (OS) were 75.5% and 81.7%, respectively. On multivariate analysis, older age, higher stage, higher grade, and malignant cytology were independent prognostic factors predictive for recurrence and poorer survival. The risk of recurrence was higher for those ≥60 versus < 60 years (hazards ratio [HR] = 1.57, 95% confidence interval [CI], 1.12–2.19), stage II (stage II: HR = 2.70, 95% CI, 1.41–5.16) versus stage IA or IB, grade 2 (HR = 1.84, 95% CI, 1.04–3.27) and grade 3 (HR = 2.47, 95% CI, 1.39–4.37) versus grade 1, and positive versus negative cytology (HR = 1.72, 95% CI, 1.21–2.45). By using these factors in a prognostic index, those with low‐risk (no or 1 risk factor), intermediate‐risk (2 factors), and high‐risk (3–4 risk factors) disease had survivals of 88%, 82%, and 75%, respectively (P < .05). CONCLUSIONS. Age, stage, grade, and cytology are important prognostic factors in high‐risk early‐stage epithelial ovarian cancer. This information may be used in the design of future clinical trials. Cancer 2008. © 2008 American Cancer Society.

show abstract

“…Patients with clear cell EOC have poorer outcomes than patients with other histologic types of EOC, regardless of tumor stage [50,51]. Because of the rarity of clear cell EOC, the safety of fertility-sparing surgery is difficult to determine in patients with early-stage clear cell EOC.…”

Section: Text Of Reviewmentioning

confidence: 99%

Fertility-Sparing Surgery for Young Women with Early-Stage Epithelial Ovarian Cancer

Nam

2013

Gynecol Obstet Invest

View full text Add to dashboard Cite

Background/Aims: To discuss the latest findings on oncologic and reproductive outcomes of fertility-sparing surgery in epithelial ovarian cancer (EOC) and to suggest proper indications for this treatment. Methods: A search of Medline database was performed for articles dealing with fertility-sparing surgery for EOC published in the English literature between January 1, 1969, and October 1, 2012. Results: To date, 918 patients with EOC underwent fertility-sparing surgery; 109 (11.9%) had disease recurrence and 48 (5.2%) died of disease. Retrospective studies suggest that fertility-sparing surgery may be safely performed in young women with a strong desire to preserve fertility and with nonclear cell histology, FIGO stage IA, IC and grade 1-2 disease or clear cell histology and FIGO stage IA disease. To date, 177 patients have succeeded in achieving 242 pregnancies, resulting in 214 term (88%) and 1 preterm (0.4%) births. Miscarriage rate was about 10% (25/242) and ectopic pregnancy rate was 0.8% (2/242) after fertility-sparing surgery. No congenital anomaly has been reported. Conclusions: Although randomized controlled trials have yet to be performed, many studies have suggested that fertility-sparing surgery is safe, with promising reproductive outcomes. Cautious selection of patients is important because of 5.2% mortality and 11% recurrence after this surgery.

show abstract

Survival and prognostic factors of early ovarian cancer

Cited by 24 publications

References 8 publications

Results of conservative treatment in epithelial ovarian carcinoma

Results of conservative treatment in epithelial ovarian carcinoma

Prognostic factors for high‐risk early‐stage epithelial ovarian cancer

Fertility-Sparing Surgery for Young Women with Early-Stage Epithelial Ovarian Cancer

Contact Info

Product

Resources

About